Page 21 - CIBEREHD2016-ENG

Hepatic and Digestive Oncology
Coordinator: Bruno Sangro Gómez-Acebo
In 2016 the groups kept up their excellence activity in both clinical and translational research. In the
field of hepatocellular carcinoma, studies have been published investigating the usefulness of liver transplantation for prevention of post-resection recurrence, the laparoscopic approach in liver donation for transplantation from live donors, options of adjuvant therapy for treatment with chemoembolisation, characterisation of computational models of intra-arterial administration of particles, utility of radioembolisation in subgroups of patients in advanced stages, and genomic hepatic characterisation with possible targets for preventive or therapeutic interventions. It is important to stress that an alarm signal of oncogenic risk associated with treatment of hepatitis C has been identified in the context of studies undertaken in the National Hepatitis Plan. In cholangiocarcinoma, the possible utility of liver transplantation for very early-stage tumours has been published or the characterisation of the change in tumour microenvironment during cholangiocarcinogenesis. The results of therapeutic interventions on rare liver diseases such as fibropolycystic liver diseases or acute intermittent porphyria have been made known, including advanced gene and cell therapy strategies, and a genetic alteration has been identified which could explain some case of hypertransaminasemia of unknown origin. In the context of colorectal cancer the EPoS project has been got under way, a multi-centre, international, controlled and randomised study intended to establish the best strategy for monitoring patients who develop high and low-risk adenomas, as well as serrated lesions. The results obtained in projects stemming from the ColonPreve project have been published, including the identification of the characteristics of endoscopists which may have an influence on the quality of endoscopy, or the assessment of the potential aid for electronic alerts in the clinical history of Primary Care for improving adhesion to screening programmes. Progress is being made in the development and validation of biomarkers of early diagnosis of colorectal cancer (EPICOLON project). Results of the research into mechanisms of resistance to chemotherapy in gastric cancer have been published as well as an analysis of the impact of the transportome in the response of gastrointestinal cancer to chemotherapy.
As regards the transfer of results, the Guides for Diagnosis and Treatment of Hepatocellular Carcinoma have been published, included in the portfolio of services of the Ministry of Health, Consumption and Equality; an international consensus document has been published on Cholangiocarcinoma and the risk stratification criteria proposed by the European Colorectal Cancer Screening Guide have been reassessed. A new method of diagnosis for pancreas cancer has been patented, and different scientific meetings have been arranged to disclose the knowledge generated. One of these deserving mention through its innovative quality is the “I International Congress of Cholangiocarcinoma”. The development of the European Network for the Study of Cholangiocarcinoma (www.enscca.org), now grouping 30 European groups and 7 North American ones, has been led, and we are taking part in the first international GWAS study on this disease.
EHD
Scientific programmes 21